Vancouver, British Columbia, Canada – Andira Pharmaceuticals is delighted to announce the appointment of Jonathan Primer, a global medical industry expert, as Lead Commercial Advisor. Mr. Primer will play a pivotal role in guiding the company through the commercialization process of its groundbreaking infection control technology, Matrix3™.
The need for innovation in infection control is urgent. The estimated direct annual cost of treating healthcare-associated infections (HAI) in the United States ranges from $ 28.4 billion to $ 45 billion, as reported by the Expert review of pharmacoeconomics & outcomes research journal.
Andira’s Founder and CEO, Dr. Dana Lambert says, “Andira has dramatically improved the antimicrobial power of silver – an agent that is currently used worldwide as a healthcare standard for infection control. Matrix3™ is a synergistic silver-based technology that provides over 1,000,000 times better antibacterial performance than conventional silver. Having Mr. Primer join Andira as lead commercial advisor validates the importance and potential of Matrix3™ technology for improving infection control in healthcare settings. Benefiting from Mr. Primer’s expertise and strategic insights, we are well-positioned to maximize market success and make substantial advancements in global health.”
Mr. Primer is a 30-year veteran of the medical products industry, serving as Group President at the global medical supply giant, Medline Industries. During this time, Medline became the largest private medical supply company in the United States. Medline has also been ranked as the 15th largest private company in North America by Forbes. Mr. Primer says, “Matrix3™ is an incredible advancement in infection control technology with potential to replace the most highly utilized silver products in healthcare. Silver wound dressings are currently a $1 billion USD global market. I look forward to helping advance commercialization of this revolutionary product.”
Matrix3™ is the world’s first broad-spectrum triple-synergy antibiotic for improved infection control. The technology incorporates silver, a standard infection control agent, and significantly improves the antibacterial effect through synergistic amplification. Matrix3™ promises to provide much needed protection against healthcare-associated infections across many commercial applications, including medical devices, wound dressings, surface coatings, and topically applied drugs.
Andira Pharmaceuticals is committed to commercializing Matrix3™ as the leading infection control solution worldwide. Matrix3™ Shield, Andira’s product line for surgical site infection, is positioned for market approval in 2026.
About Andira Pharmaceuticals:
Andira is a private pharmaceutical technology company raising the standard of medical care by applying synergistic amplification to improve existing treatments. Andira holds a global portfolio of patented and patent-pending breakthroughs for infection control, cancer therapy and enhanced drug delivery. Visit www.Andira.ca to learn more.
